Health

Senate Finance Committee Democrats are seeking evidence and proposals to shape health-care legislation. Their critique of insurers has merit, but reforms confined to insurance risk leaving hospitals, conglomerates, and much of the system’s extraction untouched, sets the stage for further disappointment.

Senate Finance Committee Democrats have invited outside evidence and proposals for their next health-care agenda. Their critique of insurers has force, but the remedies leave most of the system untouched, risking further disappointment unless reform reaches hospitals and entire conglomerates.

Global health financing is collapsing just as demands on health systems are rising. As funding retreats and reform debates intensify, a deeper question emerges about who bears the costs, and whether today’s fixes risk creating lasting damage that will be difficult to reverse.

Affordable medicines remain out of reach for millions because pharmaceutical innovation is organized around value extraction, not public health. How do shareholder-driven governance and fragmented global health financing reinforce inequity, and what structural reforms are needed to reverse it?

The global medicine-access crisis is not simply a failure to balance innovation and affordability. It reflects a deeper system in which shareholder-driven pharmaceutical governance and fragmented donor structures undermine public health and block the shift toward more equitable value creation.

Introduced by the AMA in 2001, Category III CPT codes aimed to streamline financial reporting. Instead they became entangled in a politically driven, zero-sum reimbursement game.

Health researcher Steven H. Woolf tells INET’s Lynn Parramore why making Americans healthy again means economic policies that help working- and middle-class families. Raw raw milk won’t cut it, and even being rich won’t save you. *This is Part 2 of the interview; Part 1 is here.

In a discussion with INET’s Lynn Parramore, researcher Steven H. Woolf explains how the peculiar features of life, policy, and economics in America are killing us sooner, and what we can do to change it. *This is Part 1 of a two-part interview; Part 2 is here.

Here’s the breakdown on what’s really driving America’s runaway drug prices — and whether any of the current plans stand a chance to lower your pharmacy bill.

Phillip Alvelda, a former DARPA program manager, reveals how a fracturing federal system has opened the door for bold state leadership. Will blue states rise to build a healthier, more just future?

Has the Inflation Reduction Act hindered pharmaceutical innovation? Evidence shows that the pharma industry can strategically manage disruptive change.

Misaligned incentives account for many of the most troubling features of the pharmaceutical industry’s present practices and performance.

Phillip Alvelda, a scientist and entrepreneur with past roles at NASA and DARPA, sounds the alarm on cuts that threaten the innovative capacities that have made America a global powerhouse.

The country’s flawed insurance model, driven by greed, leads to inefficiency, inequality, and denied care - a colossal scam that has sparked fury across the nation.

Dr. Victor Gurewich, a researcher and Harvard Medical School faculty member since 1965, discovered a breakthrough drug treatment for heart attacks and strokes with the potential to save millions, but institutional resistance and a U.S. healthcare system that puts profits over patients are keeping it out of reach.